Latest Noxopharm (ASX:NOX) News

Page 2 of 2

Noxopharm Advances SOF-SKN™ to Clinical Trials Amid Growing Global Collaborations

Noxopharm Limited has successfully cleared key preclinical hurdles for its SOF-SKN™ lupus drug and expanded its Sofra™ platform collaborations, supported by fresh funding to propel upcoming clinical trials.

Ada Torres

30 Apr 2025

Noxopharm’s SOF-SKN™ Clears Crucial Safety Hurdles Ahead of HERACLES Trial

Noxopharm has successfully completed key in vitro safety tests for its SOF-SKN™ lupus drug, paving the way for the upcoming HERACLES Phase 1 clinical trial.

Ada Torres

4 Feb 2025

Noxopharm Signs New Global MTAs and Boosts Cash with $2.34M R&D Rebate

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.

Ada Torres

29 Jan 2025